SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for CorMedixs DefenCath could fall sharply in 2027 has fueled a steep selloff and concern about future pricing and sales. Traders dispute how conclusive DaVitas estimate is, pointing to CMSs finalized payment rate and arguing the outlook depends on quarterly calculations and DefenCath uptake.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

FDA approval of Inovios competing RRP treatment has put Precigens PAPZIMEOS under scrutiny, with traders debating whether the new option will erode its market position. Some fear stronger competition, while others point to Precigens first-mover and full-approval advantages and question Inovios ability to commercialize its drug.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regenerons stronger-than-expected third-quarter results, supported by Eylea HD and Dupixent-related collaboration revenue, are driving a sharp breakout to multiyear highs. Traders are broadly bullish on the results and follow-through, while some question whether the gains will hold.

Zcash (ZEC) is a cryptocurrency . Users are able to generate ZEC through the process of mining. Zcash has a current supply of 16,942,077.7905448. The last known price of Zcash is 1,263.32437248 USD and is up 2.82 over the last 24 hours. It is currently trading on 668 active market(s) with $1,115,981,976.30 traded over the last 24 hours. More information can be found at https://z.cash/.

Zcash

Zcashs sharp rebound and resilience amid broader crypto weakness and Binance hack fears have traders highlighting its privacy features and speculating about a safe-haven shift into ZEC; some also point to the upcoming NU7 upgrade. Others view the rally as overextended and expect further declines.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is drawing attention after Brazil approved its Valaris merger, which traders see as a step toward closing the deal, alongside recent offshore contract wins and higher day-rate expectations. Bulls anticipate improved scale and a potential short squeeze, while skeptics point to merger-related dilution, debt and the upcoming earnings report.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxons quarterly results beat expectations, with record refining performance benefiting from tight diesel supplies amid geopolitical disruptions. Traders are broadly positive on the refining-led strength and shareholder returns, while some question whether the unusually strong margins can last.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

FLYs sharp decline is being discussed alongside weakness across the broader market and space stocks, with some traders citing inflation and interest-rate concerns. Others point to uncertainty over Alpha launch timing and execution, while bulls argue the selloff is sector-driven and note a lack of clear negative company news.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

A stronger-than-expected quarterly report and higher full-year revenue outlook, powered by demand for Mounjaro and Zepbound, have fueled LLYs rally and record highs. Traders are largely positive and cite analyst upgrades, while some question the valuation and point to trimmed profit guidance tied to acquisition-related research charges.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A rally to a fresh 52-week high ahead of an expected quarterly report has traders focused on BRIUMVI growth and whether results can justify the run; some expect an earnings-driven move, while others warn the stock may be priced for a beat. Buyout speculation and possible short covering are also fueling bullish chatter, but no deal is confirmed and the earnings timing remains uncertain.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels sharply weaker quarterly outlook, driven by soft PC demand and manufacturing constraints, triggered a steep selloff and analyst downgrades. Traders are split between calling the decline an overreaction and buying the dip, and warning that execution problems and continued weakness could bring further losses.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion.
SciSparc (NASDAQ:SPRC) shares roseread more...

Companies Pushing Experimental Treatments Toward Their Biggest Tests

These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major international brain cancer trial, Azitra (NYSEAMERICAN:AZTR) is preparing human testing of its experimental anti-wrinkle technology, ArriVent BioPharma (NASDAQ:AVBP) is reporting encouraging early response data for its gastrointestinal cancer candidate, Xencor (NASDAQ:XNCR) is advancing its experimental kidney cancer therapy toward a potential registration-enabling study, and SciSparc (NASDAQ:SPRC) is moving closer to patient enrollment in its Phase IIb Tourette syndrome trial.

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session.
Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands at $1.9read more...

Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket

Surgery Partners surged 20.6% on reported $6B Bon Secours deal talks; Scisparc and Xencor led gainers, while XP and others plunged.read more...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers

SciSparc (NASDAQ:SPRC) shares moved upwards by 28.9% to $4.68 during Thursday's pre-market session. The market value of their outstanding shares is at $2.2 million.
Valion Bio (NASDAQ:VBIO) stock increasedread more...

SciSparc Doubles Down on Agentic AI

SciSparc (NASDAQ:SPRC) is making its ambitions clear: the company wants to move beyond its traditional cannabinoid-based pharmaceutical business and explore the rapidly developing market for agentic artificial intelligence, with cybersecurity and financial technology emerging as key targets.

Investors Are Watching This High-Stakes Corner of Biotech

The race to improve therapies is heating up as Wall Street hunts for the next winners. NASDAQ:SPRC, NASDAQ:NTHI, NYSE:JNJ, NASDAQ:SMMT, NASDAQ:BNTX

AI, Biologics, and Quantum Medicine Are Fueling a New Wave of Market Movers

Healthcare and biotechnology remain especially active and offer asymmetric upside potential, as companies pursue international expansion, strategic refinancing, AI-driven operational efficiency, and next-generation pharmaceutical technologies. $TGNT, $SPRC, $WGRX, $ATPC, $SNYR, $PHR

Why SciSparc Stock Is Gaining Today

SciSparc shares are surging after it moved to acquire MUSE endoscopy IP, broadening beyond neuroscience into GERD device commercialization.read more...

SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech

Equity

In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 


SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It operates through the Drug Development and Online Sales segments. The Drug Development segment focuses on cannabinoid molecules to be approved by an official regulatory authority. The Online Sales segment consists of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

SciSparc Ltd

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>The company said it is also acquiring intellectual property rights to the MUSE system, a single-use, innovative endoscopic device.</li><li>The number of shares issued to Xylo would be 19.99% of the issued and outstanding share capital of SciSparc as of the closing date of the transaction, SciSparc said.&nbsp;</li><li>Scisparc may also issue pre-funded warrants to purchase ordinary shares at its discretion instead of issuing shares, it added.</li></ul><p><br>SciSparc Ltd. (SPRC) on Wednesday said that its majority-owned unit, NeuroThera Labs Inc., signed a binding term sheet to acquire a treasury of patents, trademarks, and intellectual property rights for innovative endoscopic systems and medical cameras from Xylo Technologies Ltd.</p><p>Shares of the company jumped as much as 34% in the pre-market session at the time of writing.</p><h2 class="st-heading-2">About The Rights And Patents</h2><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/26/3195068/0/en/SciSparc-to-Acquire-Treasury-of-Patents-for-Innovative-Medical-Endoscopy-Systems.html">said</a> it is also acquiring intellectual property rights to the MUSE system, a single-use, innovative endoscopic device designed for a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). According to SciSparc, the GERD device market is projected to reach $3.03 billion by 2030 from about $2.5 billion in 2024.</p><p>In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. The number of shares issued would be 19.99% of SciSparc's issued and outstanding share capital as of the transaction's closing date, the company said.</p><p>Scisparc may also issue pre-funded warrants to purchase ordinary shares at its discretion, rather than issuing shares. However, this is subject to negotiation and the signing of definitive acquisition agreements, the company added.</p><h2 class="st-heading-2">What Does SciSparc Intend To Do?</h2><p>Xylo had entered a licensing and distribution agreement with a Shanghai-based medical instruments company in 2019 for commercialization in Greater China.</p><p>SciSparc now intends to replicate this model across territories such as North America, Europe and Latin America by pursuing exclusive partnerships with regional distributors to accelerate worldwide commercialization.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRC">SPRC stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.</p><p>SPRC stock is down by 68% this year and by about 49% over the past 12 months.</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nyxoah-sa-stock-rises-pre-market-after-cms-raises-reimbursement-for-sleep-disorder-therapy/cL538b3REWB">Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Rising stock market chart on a trading board background.

In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 

Scisparc Ltd

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.6763
Prev Close	$0.7123
Open	$0.6769
Dividend Yield	0.00%
50-Day Moving Average	$4.17
Beta	0.80
Avg. Volume	27,208.44
PE Ratio	-0.01

52-Week High	$30.62
52-Week Low	$0.6031
Market Capitalization	$1.47M
EPS (Annual)	-$882.64
Price to Book	0.10
Revenue Per Employee	$285,333.33

Feed

News

Sentiment

Fundamentals

Info

SPRC Fundamentals